Novo 5015
Not Recruiting
75 years and younger
All
Phase
N/A
1 Location
Brief description of study
This is an interventional, 36-week, multi-national, multi-centre, randomised, 13-armed, parallel group, dose-finding phase 2 study. The study is designed to determine which dose range of NNC0519-0130 delivers the most optimal benefit risk profile for weight management in patients with obesity or overweight with weight-related comorbidities, when added as an adjunct to a reduced-calorie diet and increased physical activity.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Medical Research
-
Age: - 75 Years
-
Gender: All
TBD
Updated on
10 May 2024.
Study ID: 854910
